Clinical Trial Update: Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial studied the combination of lapatinib and MK-2206 in women with metastatic breast cancer and has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)
• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 | Status: TERMINATED